QUOTED. 3 April 2020. Minetta Liu.
Executive Summary
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.
“The promising results from this independent validation data set demonstrate the robustness of the test performance, including its ability to detect multiple cancer types and its generalizability to broader populations due to a low false-positive rate.” – Minetta Liu, professor of oncology, Mayo Clinic
Click here for a free trial of Medtech Insight